HER2-positive breast cancer: Incidence, prognosis, and treatment options. Am J Cancer 2003; 2 (3): 169-79.Estevez LG, Seidman AD. HER2-positive breast cancer: incidence, prognosis, and treatment options. Am J Cancer. 2003; 2 :169–179....
[18] Peiffer D, Howard FM, Chen N, et al. Epidemiology and prognosis of HER2-low breast cancer (BC) in the National Cancer Data Base (NCDB) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA). Abstract no:...
目前唯一可用于抗HER2治疗选择的生物标志物是HER2状态本身,但雌激素受体(estrogen receptor,ER)状态正在成为HER2+疾病中强有力的预测性标志物。近期《CLINICAL CANCER RESEARCH》上发表了一篇题目为《What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast ...
pathological complete response, and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting: A retrospective analysis. Ann Surg Oncol (2022) 29(13):8026–34. doi: 10.1245/s10434-022-12369-4
[3]Lin M, Luo T, Jin Y, et al. HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis. Cancer. 2024 Mar 15;130(6):851-862. 审批编号 CN-135074...
Loibl S, Untch M, Buyse M, et al. Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC).Cancer Res. 2020;80(4_Supplement):P5-06-02....
[8] Frenel J-S, Lusque A, Mailliez A, Bachelot T, Uwer L, Mouret-Reynier MA, et al. HER2-low metastatic breast cancer (MBC): management and prognosis of a new breast cancer entity in a real-world setting. Ann Oncol. 2021;32(5):S491. ...
The prognosis for patients with breast cancer is determined by well established path... S Loibl,L Gianni - 《American Journal of Cancer》 被引量: 7发表: 2016年 Parotid Gland Metastasis of Breast Cancer: Case Report and Review of the Literature Conclusion: Treatment with capecitabine in addition...
The role of HER2 has been most thoroughly studied in breast cancer, in which constitutively active HER2 is overexpressed in 18-22% of cases and is correlated with a poor prognosis. Hence, effective inhibition of the constitutive HER2 signaling in cancer cells has been a major goal in the ...
De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised, according to Dr. Carmen Criscitiello, European Institute of Oncology, Milan, Italy. Her comments come on the occasion of the presentation of upda